Navigation Links
Unusual Tumor-Suppressor Gene Switches Off in Lung Cancer

Researchers at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, have found a tumor suppressor gene that could be of vital significance in the development of head and neck cancers as well as lung cancer. //Their study shows that activating this particular gene could slow up the development of the aforementioned cancers.

The gene, called TCF21 is switched off in tumor cells through a process called DNA methylation. This particular process is reversible and by targeting drugs at this the development of lung cancer can be halted. Tumor-suppressor genes are basically those that prevent the cells from growing without control. When one of these genes is switched off, it could trigger the growth of cancer. In the current study, which appeared online in the January 13 early edition of the Proceedings of the National Academy of Sciences, it was found that TCF21 is pretty unusual since it can alter normal epithelial cells turning them into mesenchymal cells. This particular cell has the ability to migrate to other parts of the body. Therefore, researchers suggest that silencing the TCF21 gene can help in the cancer spreading to other parts of the body. “The fact that this gene is silenced in many cancer types strongly suggests that it plays an important role in cancer development,” said lead investigator Christoph Plass, a professor of molecular virology, immunology and medical genetics and a researcher in the OSU Human Cancer Genetics Program. First author Laura T. Smith added, "Because this gene is silenced by DNA methylation, it might be possible to reactivate it using drugs that reverse the methylation process. This could provide a new strategy for treating these cancers.” Plass' team is now looking at the role of TCF21 in the spread of cancer.

Funding from the National Cancer Institute and the National Institute of Dental and Craniofacial Research supported this research. Cont act: Darrell E. Ward, Medical Center Communications, 614-293-3737, or Darrell.Ward@osumc.eu
'"/>




Related medicine news :

1. A ‘Fit’ of Laughter Silenced by an Unusual Surgey
2. Breast Cancer Treatment Switches to more Modern Therapy
3. Master Switches Found for Adult Blood Stem Cells
4. Fibroids unlikely to Turn Cancerous
5. Virus Level could Predict Cervical Cancer Risk
6. Cancer Doctors Okays Controversial Prostate Therapy
7. Potential New Cancer Gene Identified
8. Consensus on "Combination Therapy" for Breast Cancer
9. Cancers of Colon & Rectum linked to Cigarette Smoking
10. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
11. The Cancer Rumour mill working over time
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: